抗PD-1 [5C4.B8 (Nivolumab)]組換え抗体 | Anti-PD-1 [5C4.B8 (Nivolumab)] recombinant antibody
掲載日情報：2019/10/24 現在Webページ番号：218899
Absolute Antibody社の抗PD-1 [5C4.B8 (Nivolumab)]組換え抗体(リコンビナント抗体)( Anti-PD-1 [5C4.B8 (Nivolumab)] recombinant antibody)です。
※本製品は研究用です。研究用以外には使用できません。
カートに商品を
追加しました。
追加しました。
価格
[在庫・価格 ：2025年05月09日 00時00分現在]
※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。
| 詳細 | 商品名 |
|
文献数 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Anti-PD-1, Human IgG4, Recombinant Monoclonal Antibody, clone 5C4.B8 (Nivolumab) |
|
0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Anti-PD-1, Human IgG4, Recombinant Monoclonal Antibody, clone 5C4.B8 (Nivolumab) |
|
0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
[在庫・価格 ：2025年05月09日 00時00分現在]
※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。
Anti-PD-1, Human IgG4, Recombinant Monoclonal Antibody, clone 5C4.B8 (Nivolumab)
文献数： 0
- 商品コード：Ab00791-13.12
- メーカー：ABA
- 包装：0.2mg
- 価格：¥141,000
- 在庫：無(未発注)
- 納期：2～3週間 ※※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。
- 法規制等：
| 説明文 | 別名：CD279，programmed death-1，programmed death 1，PD1，PD 1，Programmed cell death protein 1，hPD-1，hPD1，hPD 1，BMS-936558，MDX-1106，ONO-4538 クローン：5C4.B8 |
||
|---|---|---|---|
| 法規制等 | |||
| 保存条件 | -20℃ | 法規備考 | |
| 抗原種 | 免疫動物 | Human | |
| 交差性 | Cynomolgus/Human | 適用 | Blocking,FCM,IHC,SPR |
| 標識 | Unlabeled | 性状 | |
| 吸収処理 | クラス | IgG | |
| クロナリティ | Recombinant | フォーマット | |
| 掲載カタログ |
|
||
| 製品記事 | バイオシミラー関連研究用 組換えモノクローナル抗体 |
||
| 関連記事 | |||
Anti-PD-1, Human IgG4, Recombinant Monoclonal Antibody, clone 5C4.B8 (Nivolumab)
文献数： 0
- 商品コード：Ab00791-13.12-BT
- メーカー：ABA
- 包装：1mg
- 価格：ご照会ください
- 在庫：無(未発注)
- 納期：2～3週間 ※※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。
- 法規制等：
| 説明文 | 別名：CD279，programmed death-1，programmed death 1，PD1，PD 1，Programmed cell death protein 1，hPD-1，hPD1，hPD 1，BMS-936558，MDX-1106，ONO-4538 クローン：5C4.B8 |
||
|---|---|---|---|
| 法規制等 | |||
| 保存条件 | -20℃ | 法規備考 | |
| 抗原種 | 免疫動物 | Human | |
| 交差性 | Cynomolgus/Human | 適用 | Blocking,FCM,IHC,SPR |
| 標識 | Unlabeled | 性状 | |
| 吸収処理 | クラス | IgG | |
| クロナリティ | Recombinant | フォーマット | |
| 掲載カタログ |
|
||
| 製品記事 | |||
| 関連記事 | |||
カートに商品を
追加しました。
追加しました。
製品情報
| Description | Recombinant monoclonal antibody to PD-1. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 5C4.B8 (Nivolumab). |
|---|---|
| Species and Isotype | Human IgG4-P, kappa |
| Clone Number | 5C4.B8 (Nivolumab) |
| UniProt Accession Number of Target Protein | |
| Published Application(s) | IHC; FC; SPR; block |
| Published Species Reactivity | Human; cynomolgus |
| Immunogen | mAb PD1.5 was prepared by immunizing IgH and IgK knock-out transgenic mice possessing a human immunoglobulin (heavy chain) minilocus with recombinant human PD-1-Fc protein onsisting of the extracellular domain of PD-1 (amino acids 1–167) and the Fc portion of human IgG1, and Chinese hamster ovary (CHO) cells expressing human PD-1. Nivolumab was generated by grafting the variable regions of PD1.5 onto human kappa and IgG4 constant regions containing an S228P mutation (prevents Fab arm exchange with endogenous IgG4 antibodies). |
| Specificity | Nivolumab binds to the extracellular portion of human PD-1 (2.6 nM - Scatchard analysis and SPR) - the antibody also binds to cynomolgus PD-1 with a similar affinity (3.9 nM - SPR). The antibody does not bind to other immunoglobulin superfamily proteins such as CD28, CTLA-4, ICOS and BTLA. The epitope of Nivolumab for both human and cynomolgus PD-1 includes the sequences SFVLNWYR-MSPSNQTDKLAAFPEDR (aa 29-53) and SGTYLCGAISLAPKAQIKE (aa 85-103), as shown by mass spectrometry of protease-treated fragments of PD-1 - these residues are thought to additionally be important for liand binding to PD-1. PD-1 is an inhibitory receptor expressed on the surface of T cells. It is able to bind to its ligands PDL-1 and PDL-2 which results in an inhibitory signal leading to decreased T cell proliferation, cytokine protuction and cytotoxic activtiy. PDL-1 is often expressed in human tumors such as melanoma, lung and kidney where it is able to overactivate PD-1 and plays a role in the evasion of cancer cells from the immune system. |
| Application Notes | Nivolumab has been shown to bind to PD-1-expressing CHO cells (EC50 ~1.66nM). Nivolumab binds CD4+ T cells (EC50 ~0.64 nM) and stains only memory and effector, and not naiive CD4+ or CD8+ T cells from human peripheral blood by FC. The antibody is able to block the interaction between PD-1 and its ligands PDL-1 and PDL-2 (IC50 ~2.52 nM and ~2.59 nM, respectively - determined by SPR) - these IC50 values are also similar to that measured by FACS to evaluate ligand binding to PD-1 expressed on CHO cells. In an allogenic T-cell/DC MLR, Nivolumab-mediated inhibition of PD-1 results in enhancement of IFNγ release, and also enhances IL-2 secretion (97-139% over an isotype control) in response to the superantigen SEB using human peripheral blood mononuclear cells. The same is also observed in a CMV-restimulation assay. Nivolumab at very low concentrations (~1.5 ng/mL) is able to enhance T-cell reactivity in the presence of a T-cell receptor stimulus - nivolumab has no stimulatory effect in the absence of antigen or T-cell receptor stimulus. In the therapeutically used human IgG4 (S228P) format, this antibody is unable to mediate ADCC (antibody-dependent cell-mediated cytotoxicity) or CDC (complement-dependent cytotoxicity). |
| Antibody First Published in | Wang et al. In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In VivoToxicology in Non-Human Primates Cancer Immunol Res. 2014 Sep;2(9):846-56. PMID:24872026 |
| Note on publication | Describes the generation and characterization of the anti-PD-1 antibody nivolumab, including its specicity, binding affinity and its in vivo and in vitro properties. |
| Purification | Protein A affinity purified |
| Supplied in | Standard size: PBS with 0.02% Proclin 300. Bulk size: PBS only. |
| Storage Recommendation | Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C |
| Concentration | See vial label. |
カートに商品を
追加しました。
追加しました。
製品情報は掲載時点のものですが、価格表内の価格については随時最新のものに更新されます。お問い合わせいただくタイミングにより製品情報・価格などは変更されている場合があります。
表示価格に、消費税等は含まれていません。一部価格が予告なく変更される場合がありますので、あらかじめご了承下さい。